Start-up Zone

Diversity

$20 million in new funding to make clinical trials more inclusive

31 March 2023

Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital. With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements. The company will also invest in oncology-specific innovation […]

Start-up business

Institiute gives a boost to five new life science start-ups

6 March 2023

Five drug discovery companies have entered the BioInnovation Institute’s (BII) Venture Lab acceleration programme for early-stage companies as part of a cohort of ten new members.  The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of €500,000 plus access to […]

Senior couple jogging

Anti-ageing therapeutics company completes seed funding

28 February 2023

Five Alarm Bio (FAB) has completed a seed investment round, raising over £500K ($605K). The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. Investors include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom, as well as other Angel […]

""

Turning science into business: Merging AI and RNA

27 February 2023

New kids on the block, Atomic AI, recently closed a $35 million series A financing. DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models.  DS: Congratulations on closing a […]

Researcher pipetting samples in microplate

Start-up aims to advance transformative genetic medicines

16 February 2023

Aera Therapeutics has launched with a vision to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas”.   The company’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang and aims to address the limitations of today’s delivery technologies to more broadly enable new […]

Improving clinical trials through patient experience

9 February 2023

Stitch Health is a London-based start-up, on a mission to improve clinical trials by measuring and surfacing each patient’s experience. DDW’s Megan Thomas caught up with Jonathan Moshinsky, Co-Founder and CEO.  MT: Near the end of 2022, Stitch closed £2.5 million seed funding to create the definitive patient retention platform for clinical trials. What causes […]

T cells attack a cancer cell

$49 million raised to fund original immuno-oncology approach

31 January 2023

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.   Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of […]

Woman tests blood glucose level

Start-up hopes novel drug could treat cause of type 2 diabetes

30 January 2023

Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities.  Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023 with the final report in June 2023.   The […]

""

What Lithuania offers life sciences start-ups

30 January 2023

DDW Editor Reece Armstrong takes a look at Lithuania’s life sciences sector and what it means for start-ups operating in the country. A one to watch, would be my first thoughts when thinking about Lithuania and its start-up sector. After a visit to the country, in which I was able to tour some of the various […]

Gene therapy

$5 million raised towards gene therapies for muscular diseases

27 January 2023

Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.  The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.  “Built on decades of expertise in neuromuscular diseases, […]

RNA

$35 million to advance AI-driven RNA structure platform

26 January 2023

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round.  The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO Nat Friedman, Doug Mohr, Curai […]

Preterm infant in the neonatal unit

Neonatal therapeutics company raises $35 million

22 December 2022

Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.   The capital will be used to continue preclinical work conducted through the seed investment with the Xontogeny development team and to […]

Protein

Therapeutic protein project joins Bio Studio programme

20 December 2022

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of Washington’s Institute for Protein Design. […]

Human antibodies

Start-up focusses on human-derived antibody drugs

7 December 2022

Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based drugs, but the limited number […]

Pedro Correa de Sampaio and Annelise Soulier

Start-up raises £520K to improve immunotherapy outcomes

28 November 2022

Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours.  While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not respond to them. Neobe was founded by Pedro […]

""

New biotech aspires to reveal insights into disease biology

18 November 2022

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the […]

« Previous
Next »